1. Home
  2. CADL
  3. CADL News

Latest Candel Therapeutics Inc. (CADL) News on October 8, 2025

One Candel Therapeutics Insider Raised Stake By 22% In Previous Year
CADL

Simply Wall St.

3 months ago

One Candel Therapeutics Insider Raised Stake By 22% In Previous Year

Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know
CADL

Zacks

3 months ago

Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know

CADL

MT Newswires

3 months ago

Candel Therapeutics Expects to Raise $15 Million From Direct Offering

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
CADL

GlobeNewswire

3 months ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

CADL

MT Newswires

4 months ago

Candel Therapeutics Names Charles Schoch Chief Financial Officer

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
CADL

GlobeNewswire

4 months ago

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
CADL

GlobeNewswire

4 months ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?
CADL

Zacks

4 months ago

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?

Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer
CADL

Insider Monkey

4 months ago

Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
CADL

Zacks

4 months ago

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

CADL

MT Newswires

4 months ago

Candel Says FDA Grants Regenerative Medicine Advanced Therapy Designation to Prostate Cancer Drug

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
CADL

GlobeNewswire

4 months ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
CADL

GlobeNewswire

4 months ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025
CADL

Insider Monkey

5 months ago

Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
CADL

GlobeNewswire

5 months ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Best Momentum Stocks to Buy for May 19th
CADL

Zacks

5 months ago

Best Momentum Stocks to Buy for May 19th

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
CADL

GlobeNewswire

5 months ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics to Present at Upcoming Investor Conferences
CADL

GlobeNewswire

5 months ago

Candel Therapeutics to Present at Upcoming Investor Conferences

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
CADL

GlobeNewswire

5 months ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
CADL

GlobeNewswire

6 months ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients
CADL

Benzinga

6 months ago

Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients

CADL

MT Newswires

6 months ago

Candel Therapeutics Reports Final Phase 2a Survival Data for Lung Cancer Treatment

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
CADL

GlobeNewswire

6 months ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now
CADL

Zacks

6 months ago

Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now

CADL

MT Newswires

7 months ago

Candel Therapeutics Partners With IDEA Pharma for CAN-2409 Commercialization

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
CADL

GlobeNewswire

7 months ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
CADL

GlobeNewswire

7 months ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
CADL

GlobeNewswire

7 months ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them.
CADL

Simply Wall St.

7 months ago

Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them.

Candel Therapeutics stock drops despite OS improvement in PDAC trial
CADL

Clinical Trials Arena

7 months ago

Candel Therapeutics stock drops despite OS improvement in PDAC trial

CADL

MT Newswires

7 months ago

Candel Therapeutics Shares Fall After Final Pancreatic Cancer Survival Data

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
CADL

GlobeNewswire

7 months ago

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

CADL

MT Newswires

8 months ago

Citigroup Initiates Candel Therapeutics at Buy With $25 Price Target

Insider Stock Buying Of Candel Therapeutics Delivers Return On US$3.00m Investment
CADL

Simply Wall St.

9 months ago

Insider Stock Buying Of Candel Therapeutics Delivers Return On US$3.00m Investment

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
CADL

GlobeNewswire

9 months ago

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win
CADL

Pharma Voice

9 months ago

After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win

CADL

MT Newswires

10 months ago

Candel Therapeutics Closes Securities Offering to Raise $92 Million

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CADL

GlobeNewswire

10 months ago

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

CADL

MT Newswires

10 months ago

Update: Candel Therapeutics Prices $80 Million Public Offering -- Shares Fall

CADL

MT Newswires

10 months ago

Top Midday Decliners

CADL

MT Newswires

10 months ago

Sector Update: Health Care Stocks Steady Premarket Friday

CADL

MT Newswires

10 months ago

Candel Therapeutics Prices $80 Million Public Offering

Candel Therapeutics Announces Pricing of Public Offering
CADL

GlobeNewswire

10 months ago

Candel Therapeutics Announces Pricing of Public Offering

Candel Therapeutics Announces $80 Million Proposed Public Offering
CADL

GlobeNewswire

10 months ago

Candel Therapeutics Announces $80 Million Proposed Public Offering

CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
CADL

Zacks

10 months ago

CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal

Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug
CADL

Investor's Business Daily

10 months ago

Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug

CADL

MT Newswires

10 months ago

Sector Update: Health Care Stocks Softer Late Afternoon

CADL

MT Newswires

10 months ago

Top Midday Gainers

Candel Therapeutics Prostate Cancer Therapy Shows Promise
CADL

Exec Edge

10 months ago

Candel Therapeutics Prostate Cancer Therapy Shows Promise

Candel Therapeutics Prostate Cancer Therapy Shows Promise
CADL

Exec Edge

10 months ago

Candel Therapeutics Prostate Cancer Therapy Shows Promise

Candel Therapeutics stock up 172% after Phase III prostate cancer success
CADL

Clinical Trials Arena

10 months ago

Candel Therapeutics stock up 172% after Phase III prostate cancer success

CADL

MT Newswires

10 months ago

Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday

Candel Therapeutics Stock Surges Over 100% - Here's Why
CADL

Benzinga

10 months ago

Candel Therapeutics Stock Surges Over 100% - Here's Why

Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug
CADL

Investor's Business Daily

10 months ago

Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug

CADL

MT Newswires

10 months ago

Candel Therapeutics Says Prostate Cancer Drug Trial Meets Primary Endpoint; Shares Jump

CADL

MT Newswires

10 months ago

Top Premarket Gainers

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
CADL

GlobeNewswire

10 months ago

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
CADL

GlobeNewswire

a year ago

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
CADL

GlobeNewswire

a year ago

Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
CADL

GlobeNewswire

a year ago

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Candel Therapeutics Advances in Cancer Treatment Trials
CADL

TipRanks

a year ago

Candel Therapeutics Advances in Cancer Treatment Trials

Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
CADL

GlobeNewswire

a year ago

Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
CADL

GlobeNewswire

a year ago

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

Candel Therapeutics, Inc. (NASDAQ:CADL) most popular amongst individual investors who own 48%, insiders hold 30%
CADL

Simply Wall St.

a year ago

Candel Therapeutics, Inc. (NASDAQ:CADL) most popular amongst individual investors who own 48%, insiders hold 30%

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
CADL

GlobeNewswire

a year ago

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
CADL

GlobeNewswire

a year ago

Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

CADL

MT Newswires

a year ago

Candel Therapeutics Shares Rise After Q2 Results

Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
CADL

GlobeNewswire

a year ago

Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
CADL

GlobeNewswire

a year ago

Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Candel Therapeutics' (NASDAQ:CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
CADL

ACCESSWIRE

a year ago

Candel Therapeutics' (NASDAQ:CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

Candel Therapeutics to Join Russell 3000® Index
CADL

GlobeNewswire

a year ago

Candel Therapeutics to Join Russell 3000® Index

Lotto 6/49 - $64 million up for grabs in the next draw!
CADL

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
CADL

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
CADL

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
CADL

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
CADL

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
CADL

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
CADL

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
CADL

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
CADL

ACCESSWIRE

a year ago

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

CADL

MT Newswires

a year ago

FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma

FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
CADL

GlobeNewswire

a year ago

FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma

Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
CADL

Zacks

a year ago

Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why

Candel (CADL) Reports Upbeat Data From Lung Cancer Study
CADL

Zacks

a year ago

Candel (CADL) Reports Upbeat Data From Lung Cancer Study

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
CADL

GlobeNewswire

a year ago

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
CADL

GlobeNewswire

a year ago

Candel Therapeutics to Present at the Jefferies Global Healthcare Conference

Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
CADL

GlobeNewswire

a year ago

Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting

Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
CADL

GlobeNewswire

a year ago

Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
CADL

GlobeNewswire

a year ago

Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
CADL

Zacks

a year ago

Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
CADL

GlobeNewswire

a year ago

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
CADL

GlobeNewswire

a year ago

Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

Retail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too were rewarded
CADL

Simply Wall St.

2 years ago

Retail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too were rewarded

Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
CADL

Zacks

2 years ago

Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study

After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study
CADL

Benzinga

2 years ago

After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
CADL

GlobeNewswire

2 years ago

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
CADL

GlobeNewswire

2 years ago

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
CADL

GlobeNewswire

2 years ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
CADL

GlobeNewswire

2 years ago

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
CADL

GlobeNewswire

2 years ago

CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

Share on Social Networks: